Clinical trial
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung…
NCT00068653 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00068653 |
|---|---|
| Title | Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer |
| Official title | Phase II Study of the Combination of ZD1839 (Iressa) and Celecoxib in Patients With Platinum Refractory Non-Small Cell Lung Cance |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Celecoxib, ZD1839 |
| Enrollment | 27 |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Sep 11, 2003 |
| Last update posted | Apr 29, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: